Ifunanya Okafor26 February 2025
AstraZeneca’s experimental treatment, camizestrant, has shown significant promise in improving survival for patients with advanced hormone receptor-positive, HER2-negative breast cancer, according to interim results from a late-stage clinical trial. The SERENA-6 trial tested camizestrant in combination with a standard-of-care therapy that suppresses tumor growth proteins. The study found that the drug improved progression-free survival, meaning […]
